Dr. Zev Wainberg

A novel pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a study of 500 patients. The drug, which targets a mutated protein common in pancreatic cancer, showed fewer severe side effects and is being considered a new standard of care. The FDA plans to expedite its review, and the Food and Drug Administration is allowing expanded access for eligible patients.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy, with fewer severe side effects. The drug, which targets a mutated protein common in pancreatic cancer, is being fast-tracked for FDA review and has shown improved quality of life for patients.